Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation

Journal of Drug Targeting

Volumn 24, Issue 8, 2016, Pages 730-743

  Pawar, Smita ^a   Shevalkar, Ganesh ^a   Vavia, Pradeep ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Bioavailability; doxorubicin; N lauryl glucosamine; niosomes; targeted drug delivery system

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CATALASE; CREATINE KINASE; DAUNORUBICIN; DOXORUBICIN; GLUCOSAMINE; LACTATE DEHYDROGENASE; MALONALDEHYDE; NIOSOME; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; LIPOSOME; NANOMATERIAL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SIZE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MELANOMA; MOUSE; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; ANIMAL; BIOAVAILABILITY; CHEMISTRY; EXPERIMENTAL MELANOMA; INBRED MOUSE STRAIN; MOLECULARLY TARGETED THERAPY; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; FEMALE; GLUCOSAMINE; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE, INBRED STRAINS; MOLECULAR TARGETED THERAPY; NANOSTRUCTURES; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84961202438     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2016.1154560     Document Type: Article

References (56)

1. G.Hortobagyi Anthracyclines in the treatment of cancer. Drugs 1997;54:1–7.
2. V.G.Kaklamani, W.J.Gradishar Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003;4:S26–33.
3. C.F.Thorn, C.Oshiro, S.Marsh,. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genom 2011;21:440–446.
4. D.Bagchi, M.Bagchi, E.Hassoun,. Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology 1995;95:1–9.
5. X.-B.Xiong, Z.Ma, R.Lai, A.Lavasanifar The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 2010;31:757–68.
6. R.Duncan, S.C.Richardson Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol Pharma 2012;9:2380–402.
7. G.Sahay, D.Y.Alakhova, A.V.Kabanov Endocytosis of nanomedicines. J Control Release 2010;145:182–95.
8. K.Greish Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457–64.
9. J.D.Byrne, T.Betancourt, L.Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008;60:1615–26.
10. D.M.Webster, P.Sundaram, M.E.Byrne Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 2013;84:1–20.
11. D.Pramanik, N.R.Campbell, S.Das,. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 2012;3:640–50.
12. P.Tardi, N.Boman, P.Cullis Liposomal doxorubicin. J Drug Target 1996;4:129–40.
13. S.Fukushima, M.Machida, T.Akutsu,. Roles of adriamycin and adriamycin dimer in antitumor activity of the polymeric micelle carrier system. Colloids Surf B 1999;16:227–36.
14. J.Khandare, T.Minko Polymer–drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 2006;31:359–97.
15. L.Tavano, M.Vivacqua, V.Carito,. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloids Surf B Biointerfaces 2013;102:803–7.
16. T.Liu, R.Guo Preparation of a highly stable niosome and its hydrotrope-solubilization action to drugs. Langmuir 2005;21:11034–9.
17. G.Parthasarathi, N.Udupa, P.Umadevi, G.Pillai Pharmacokinetic evaluation of surfactant vesicles containing methotrexate in tumor bearing mice. Int J Pharm 1990;61:75–80.
18. G.Parthasarathi, N.Udupa, P.Umadevi, G.Pillai Niosome encapsulated of vincristine sulfate: improved anticancer activity with reduced toxicity in mice. J Drug Target 1994;2:173–82.
19. A.Azeem, M.K.Anwer, S.Talegaonkar Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target 2009;17:671–89.
20. T.T.Pham, C.Jaafar-Maalej, C.Charcosset, H.Fessi Liposome and niosome preparation using a membrane contactor for scale-up. Colloids Surf B 2012;94:15–21.
21. B.Mukherjee, B.Patra, B.Layek, A.Mukherjee Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. Int J Nanomed 2007;2:213–25.
22. D.-S.Kim, K.-S.Park, K.-C.Jeong,. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009;273:243–9.
23. J.M.Brown, A.J.Giaccia The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408–16.
24. H.-C.Wu, D.-K.Chang, C.-T.Huang Targeted therapy for cancer. J Cancer Mol 2006;2:57–66.
25. V.Ganapathy, M.Thangaraju, P.D.Prasad Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009;121:29–40.
26. L.M.Ferreira Cancer metabolism: the Warburg effect today. Exp Mol Pathol 2010;89:372–80.
27. US20100016249A1. Cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof. 2006.
28. K.Hulikova, J.Svoboda, V.Benson,. N-acetyl-D-glucosamine-coated polyamidoamine dendrimer promotes tumor-specific B cell responses via natural killer cell activation. Int Immunopharmacol 2011;11:955–61.
29. S.Yomogida, J.Hua, K.Sakamoto, I.Nagaoka Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-α-stimulated human colonic epithelial HT-29 cells. Int J Mol Med 2008;22:205–11.
30. I.F.Uchegbu, S.P.Vyas Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharmaceut 1998;172:33–70.
31. S.Pawar, P.Vavia Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin. J Drug Target 2016;24:68–79.
32. T.Uchimura, M.Kato, T.Saito, H.Kinoshita Prediction of human blood-to-plasma drug concentration ratio. Biopharm Drug Dispos 2010;31:286–97.
33. H.S.Yoo, K.H.Lee, J.E.Oh, T.G.Park In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 2000;68:419–31.
34. P.D.Henry, C.M.Bloor, B.E.Sobel Increased serum creatine phosphokinase activity in experimental pulmonary embolism. Am J Cardiol 1970;26:151–5.
35. H.Husdan, A.Rapoport Estimation of creatinine by the Jaffe reaction a comparison of three methods. Clin Chem 1968;14:222–38.
36. L.Pine, P.Hoffman, G.Malcolm,. Determination of catalase, peroxidase, and superoxide dismutase within the genus Legionella. J Clin Microbiol 1984;20:421–9.
37. R.F.Beers, I.W.Sizer A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 1952;195:133–40.
38. A.Papastergiadis, E.Mubiru, H.Van Langenhove, B.De Meulenaer Malondialdehyde measurement in oxidized foods: evaluation of the spectrophotometric thiobarbituric acid reactive substances (TBARS) test in various foods. J Agric Food Chem 2012;60:9589–94.
39. I.Rahman, A.Kode, S.K.Biswas Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006;1:3159–65.
40. M.Zykova, O.Ipatova, V.Prozorovskii,. Changes of doxorubicin distribution in blood and plasma after its inclusion into nanophospholipid formulations. Biochem (Moscow) Suppl Ser B: Biomed Chem 2012;6:39–41.
41. B.Marafino, S.Giri, D.Siegel Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. J Pharmacol Exp Ther 1981;216:55–61.
42. A.Rahman, D.Carmichael, M.Harris, J.K.Roh Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1986;46:2295–9.
43. D.Yesair, E.Schwartzbach, D.Shuck,. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res 1972;32:1177–83.
44. F.Danhier, O.Feron, V.Préat To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148:135–46.
45. E.G.Mimnaugh, T.E.Gram, M.A.Trush Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs: characterization and effects of reactive oxygen scavengers. J Pharmacol Exp Ther 1983;226:806–16.
46. S.Ayla, I.Seckin, G.Tanriverdi,. Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. Int J Cell Biol 2011:390238.
47. C.Vergely, S.Delemasure, Y.Cottin, L.Rochette Preventing the cardiotoxic effects of anthracyclines: from basic concepts to clinical data. Heart Metab 2007;35:1–7.
48. A.M.Rahman, S.W.Yusuf, M.S.Ewer Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2007;2:567–83.
49. R.C.Bast, D.W.Kufe, R.E.Pollock, eds. etal. Holland-Frei cancer medicine. 5th ed. 2 v.(xxiv). Hamilton (ON): BC Decker; 2000:2640–99.
50. F.Villani, M.Galimberti, P.Poggi,. The effect of superoxide dismutase and catalase on the delayed toxicity of doxorubicin. Cardiologia (Rome, Italy) 1992;37:709–11.
51. Y.Kalender, M.Yel, S.Kalender Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 2005;209:39–45.
52. E.Van Cutsem, J.Arends The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005;9:S51–63.
53. E.H.Mathews, L.Liebenberg, R.Pelzer High-glycolytic cancers and their interplay with the body's glucose demand and supply cycle. Med Hypoth 2011;76:157–65.
54. R.A.Medina, G.I.Owen Glucose transporters: expression, regulation and cancer. Biol Res 2002;35:9–26.
55. D.Rivenzon-Segal, E.Rushkin, S.Polak-Charcon, H.Degani Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol-Endocrinol Metabol 2000;279:E508–19.
56. S.K.Pawar, A.J.Badhwar, F.Kharas,. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery. Int J Pharmaceut 2012;436:183–93.